OncologyPRO: The home of ESMO’s educational and scientific resources

From ESMO Breast Cancer 2022:
For patients with hormone receptor-positive, HER2-negative advanced breast cancer, the addition of ribociclib to fulvestrant continues to significantly improves overall survival after more than 70 months

From ESMO Breast Cancer 2022:
Preliminary phase Ib/II trial results suggest that first-line treatment with datopotamab deruxtecan plus durvalumab is active against locally advanced and metastatic triple-negative breast cancer

From ESMO Breast Cancer 2022:
Trastuzumab deruxtecan may help control intracranial metastases in patients with HER2-positive breast cancer

From ESMO Breast Cancer 2022:
Patients recruited to the monarchE trial on the basis of a high clinicopathological risk of early breast cancer recurrence derive a significant invasive disease-free survival benefit from abemaciclib use

From ESMO Breast Cancer 2022:
A single dose of HER3-targeted antibody–drug conjugate induces a CelTIL response in treatment-naïve early-stage hormone receptor-positive, HER2-negative breast cancer

From the 2022 AACR Annual Meeting:
A bispecific antibody targeting PD-1 and CTLA-4 has shown peripheral T-cell proliferation and anti-tumour activity in a range of advanced cancers

From the 2022 AACR Annual Meeting:
Combining neoadjuvant durvalumab with oleclumab, monalizumab or danvatirsen may offer novel strategies for early-stage NSCLC

From the 2022 AACR Annual Meeting:
Olaparib given with metronomic cyclophosphamide and metformin may have activity against recurrent, advanced endometrial cancer